Opinion

Video

Managing Toxicities of Hydroxyurea in Patients With PV

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Related Videos
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Al Malki
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
MDS/CMML | Corona Borealis – stock.adobe.com
February 7th 2025

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
February 5th 2025

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

The OncFive: OncLive's Top Oncology Articles for the Week of 1/19
January 25th 2025

The OncFive: Top Oncology Articles for the Week of 1/19

FDA
January 24th 2025

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS